MedTrace Logo

Ivabradine in Patients With Congestive Heart Failure

NCT04448899 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-08-04

No results posted yet for this study

Summary

The aim of this study is to assess the efficacy of Ivabradine therapy in patients with congestive heart failure using the cardiac biomarkers NT-Pro BNP and Neopterin.

Conditions

  • Congestive Heart Failure

Interventions

DRUG

Ivabradine Oral Tablet

Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability plus their standard treatment.

DRUG

Blacebo plus standard treatment

Blacebo plus standard treatment

Sponsors & Collaborators

  • Damanhour University

    lead OTHER

Principal Investigators

  • Rehab Werida, Lecturer · Damanhour University, Faculty of Pharmacy

  • Jayda M Dogheim, B. Pharm · Alexandria University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2021-02-01
Completion
2021-02-05

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04448899 on ClinicalTrials.gov